Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘LODR Regulations’) and in furtherance to the disclosure made in the Prospectus filed with the Securities Exchange Board of India, during the Initial Public Offer of the Company, Emcure Pharmaceuticals has informed that Marcan Pharmaceuticals Inc., a subsidiary of the Company (‘Marcan’) has on July 02, 2026 (EDT) entered into share purchase agreements with certain shareholders of Mantra Pharma Inc., a step-down subsidiary of the Company (‘Mantra’), to acquire all of Class E Special Shares in the share capital of Mantra. Consequently, Mantra continues to be 100% subsidiary of Marcan. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in Annexure A, enclosed.
The above information is a part of company’s filings submitted to BSE.
